TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28669689

Group type: EXPERIMENTAL
Intervention: rHuEPO (epoetin β; mean dose 6000 IU per week)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (0·9% NaCl)
Number of subjects: 48
Study: 25279395

Group type: EXPERIMENTAL
Intervention: CHX 0.2% rinse with alcohol (CHX1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CHX 0.2% rinse without alcohol (CHX2)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CHX 0.2% rinse with antidiscolouration system (CHX3)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline rinse (CTRL)
Number of subjects: 70
Study: 23439901

Group type: EXPERIMENTAL
Intervention: SBME mastery learning for infant lumbar puncture (ILP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group for ILP (no SBME mastery learning)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: SBME mastery learning for child intravenous line placement (CIV)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group for CIV (no SBME mastery learning)
Number of subjects: 200
Study: 21739598

Group type: EXPERIMENTAL
Intervention: Daily oral antioxidant supplementation (900 IU of alpha‐tocopherol, 200 mg of ascorbic acid, and 600 mg of alpha‐lipoic acid)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 19545481

Group type: EXPERIMENTAL
Intervention: Group-based mindfulness training (twice-weekly sessions for 5 weeks, plus home practice)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Waiting list for therapy
Number of subjects: 22
Study: 16481635

Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation (1000 mg of elemental calcium as calcium carbonate with 400 IU of vitamin D3 daily)
Number of subjects: 36282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282
Study: 15318466

Group type: EXPERIMENTAL
Intervention: Sevoflurane 5% with nitrous oxide (N2O) 65% in O2
Number of subjects: 44

Group type: COMPARATOR
Intervention: Propofol 2 mg kg(‐1) intravenously
Number of subjects: 44
Study: 11522563

Group type: EXPERIMENTAL
Intervention: Formula containing 544 kJ x kg(‐1) x d(‐1) with 65% of nonprotein energy as carbohydrate
Number of subjects: 62

Group type: COMPARATOR
Intervention: Formula containing 544 kJ x kg(‐1) x d(‐1) with 35% of nonprotein energy as carbohydrate
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Formula containing 648 kJ x kg(‐1) x d(‐1) with 35% of nonprotein energy as carbohydrate
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Formula containing 648 kJ x kg(‐1) x d(‐1) with 65% of nonprotein energy as carbohydrate
Number of subjects: 62
Study: 9300474

Group type: EXPERIMENTAL
Intervention: Roller pump
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Centrifugal pump
Number of subjects: 46
Study: 8282920

Group type: EXPERIMENTAL
Intervention: Erection enhancement pill
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Erection detraction pill
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 20
Study: 3553039

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 29929437

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - participated in six group sessions with an active peer model, received exercise prescription and PA information
Number of subjects: 52

Group type: COMPARATOR
Intervention: Attention Control Group (ACG) - received health information
Number of subjects: 52
Study: 27313282

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 10942

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10942
Study: 24694983

Group type: EXPERIMENTAL
Intervention: Colchicine (0·5 mg twice daily for patients >70 kg or 0·5 mg once daily for patients ≤70 kg)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 22541841

Group type: EXPERIMENTAL
Intervention: Oral naloxone 5 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oral naloxone 20 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oral naloxone 40 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oral naloxone 80 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oral naloxone 120 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Rectal naloxone (dose not specified)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intravenous naloxone 1 mg
Number of subjects: 28
Study: 20822879

Group type: EXPERIMENTAL
Intervention: Parental factors
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Adolescent substance use severity
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Externalizing disorders
Number of subjects: 310
Study: 18392039

Group type: EXPERIMENTAL
Intervention: Cranberry extract tablets
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 16019862

Group type: EXPERIMENTAL
Intervention: Local hyperthermia treatment (30-min sessions twice a week for 5 weeks, total of 20 sessions at 39-40 degrees C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intra-plaque infiltrations using 10 mg verapamil (one infiltration once a week for 3 months)
Number of subjects: 60
Study: 12969043

Group type: EXPERIMENTAL
Intervention: Sacrococcygeal local anaesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 60
Study: 10807619

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate 500 microgram twice daily
Number of subjects: 751

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 751
Study: 8806933

Group type: COMPARATOR
Intervention: 10% glucose (CHO)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 4.3% medium-chain triglycerides (MCTs)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 10% glucose + 4.3% MCTs (CHO+MCT)
Number of subjects: 6
Study: 1640130

Group type: EXPERIMENTAL
Intervention: Bolus injection of midazolam
Number of subjects: 41

Group type: COMPARATOR
Intervention: Bolus injection followed by continuous infusion of midazolam
Number of subjects: 41
Study: 6696291

Group type: EXPERIMENTAL
Intervention: Inhaled diphemanil (2 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 20
Study: 29395182

Group type: EXPERIMENTAL
Intervention: Iron supplementation in infancy
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Iron deficiency with or without anemia at 12 or 18 months
Number of subjects: 1018
Study: 27876353

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell (MNC) injections intradermally
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo injections intradermally
Number of subjects: 38
Study: 24872562

Group type: EXPERIMENTAL
Intervention: fMRI analysis of prefrontal cortex value signals while imagining pleasure from engaging activities and snack foods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: fMRI analysis of prefrontal cortex value signals
Number of subjects: 0
Study: 22481421

Group type: COMPARATOR
Intervention: Procaine penicillin (50,000 units/kg OD IM) and gentamicin (5 mg/kg OD IM)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (50 mg/kg OD IM)
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Oral trimethoprim-sulfamethoxazole (TMP-SMX) at 10 mg/kg/day divided twice daily and gentamicin IM OD
Number of subjects: 434
Study: 19917596

Group type: EXPERIMENTAL
Intervention: Trauma-focused treatment
Number of subjects: 353

Group type: COMPARATOR
Intervention: Health education group treatment
Number of subjects: 353
Study: 18401254

Group type: EXPERIMENTAL
Intervention: Sedatives and opioids
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Sedatives
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: NMBAs
Number of subjects: 549
Study: 15944633

Group type: EXPERIMENTAL
Intervention: Video informed consent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional verbal informed consent
Number of subjects: 0
Study: 12857428

Group type: EXPERIMENTAL
Intervention: Metformin (1500 mg/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no metformin)
Number of subjects: 17
Study: 10475317

Group type: EXPERIMENTAL
Intervention: Propofol plus fentanyl (100 microg) with 1.5% lidocaine and epinephrine test dose
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Propofol with 1.5% lidocaine and epinephrine test dose
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline control group (3 mL isotonic sodium chloride solution)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (propofol and propofol-fentanyl) with test dose
Number of subjects: 80
Study: 7815584

Group type: EXPERIMENTAL
Intervention: 15% and 20% papaverine base gel applied to the scrotum, perineum, and penis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 15% and 20% papaverine base gel
Number of subjects: 20
Study: 1941852

Group type: EXPERIMENTAL
Intervention: Intralesional interferon alpha-2b (1.5 million units, nine injections)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intralesional interferon alpha-2b
Number of subjects: 11
Study: 7017781

Group type: EXPERIMENTAL
Intervention: Fluproquazone (100 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg)
Number of subjects: 31
Study: 30589790

Group type: EXPERIMENTAL
Intervention: Acetyl-L-Carnitine 3000 mg/day for 2 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27680418

Group type: EXPERIMENTAL
Intervention: High-pitch computed tomography (HPCT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional multidetector computed tomography (MDCT)
Number of subjects: 55
Study: 25534726

Group type: EXPERIMENTAL
Intervention: 500 mg nemonoxacin
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 750 mg nemonoxacin
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 650 mg nemonoxacin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 23208803

Group type: EXPERIMENTAL
Intervention: Medpor (porous polyethylene) implantation for inferior turbinate reconstruction
Number of subjects: 19
Study: 21107298

Group type: EXPERIMENTAL
Intervention: SCE‐A vaginal cream (1 g once daily for 7 days, then twice weekly for 27 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.3 mg SCE‐A oral tablets (once daily for 27 days)
Number of subjects: 0
Study: 19365317

Group type: EXPERIMENTAL
Intervention: Laparoscopic antireflux surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open antireflux surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best medical therapy (proton pump inhibitors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete wrap (Nissen's fundoplication)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial fundoplication (Toupet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antireflux surgery
Number of subjects: 0
Study: 17065847

Group type: EXPERIMENTAL
Intervention: Valacyclovir 1.0 g daily for 6 months
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 14742366

Group type: EXPERIMENTAL
Intervention: i.v. parecoxib 40 mg followed by oral valdecoxib 40 mg
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study: 12681184

Group type: EXPERIMENTAL
Intervention: Infant Flow (IF)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Medijet (MJ)
Number of subjects: 125
Study: 10467840

Group type: EXPERIMENTAL
Intervention: Serum adenosine deaminase (ADA) activity
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Serum ADA level > or = 53.76 U/l
Number of subjects: 20
Study: 7786522

Group type: EXPERIMENTAL
Intervention: 3% Tiacrilast hydrogel
Number of subjects: 31

Group type: COMPARATOR
Intervention: Hydrogel alone
Number of subjects: 31
Study: 2079774

Group type: EXPERIMENTAL
Intervention: Alcohol (mean blood alcohol level approximately 69.5 mg%; SE 6.20 mg%)
Number of subjects: 17
Study: 540702

Group type: EXPERIMENTAL
Intervention: Isoproterenol (I) (0.02 microgram/kg/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dopamine (DP) (5 microgram/kg/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Dobutamine (DB) (5 microgram/kg/min)
Number of subjects: 12
Study: 30770519

Group type: EXPERIMENTAL
Intervention: IV golimumab 2 mg/kg at weeks 0, 4, 12, and 20
Number of subjects: 474

Group type: COMPARATOR
Intervention: IV placebo
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: IV golimumab
Number of subjects: 474
Study: 28096029

Group type: EXPERIMENTAL
Intervention: COPD‐GRIP intervention
Number of subjects: 24
Study: 26433431

Group type: EXPERIMENTAL
Intervention: Daptomycin (4 mg/kg once)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vancomycin (15 mg/kg every 12 h)
Number of subjects: 100
Study: 23400985

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia (CSE)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 800
Study: 21231927

Group type: EXPERIMENTAL
Intervention: FCM (Fludarabine, Cyclophosphamide, Mitoxantrone)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: FCM
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: FCM-R
Number of subjects: 52
Study: 20030496

Group type: EXPERIMENTAL
Intervention: Continuous use of the diaphragm
Number of subjects: 0
Study: 17177298

Group type: EXPERIMENTAL
Intervention: Tritherapy including amantadine (interferon, ribavirin, and amantadine)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Bitherapy (interferon and ribavirin)
Number of subjects: 2
Study: 15189387

Group type: EXPERIMENTAL
Intervention: Evidence-based programme on aspects of EBP including literature searching and critical appraisal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard in-service training package on the management of common knee pathologies
Number of subjects: 30
Study: 11438340

Group type: EXPERIMENTAL
Intervention: IUI-ready sperm
Number of subjects: 209

Group type: COMPARATOR
Intervention: Conventional sperm
Number of subjects: 209
Study: 9602597

Group type: EXPERIMENTAL
Intervention: 1 or 2 MAC of isoflurane in nitrous oxide
Number of subjects: 21

Group type: COMPARATOR
Intervention: No volatile agent
Number of subjects: 21
Study: 30799401

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) program
Number of subjects: 172

Group type: COMPARATOR
Intervention: Traditional care (control)
Number of subjects: 172
Study: 31577874

Group type: EXPERIMENTAL
Intervention: Ligelizumab 24 mg
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Ligelizumab 72 mg
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Ligelizumab 240 mg
Number of subjects: 382

Group type: COMPARATOR
Intervention: Omalizumab 300 mg
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study: 28522352

Group type: EXPERIMENTAL
Intervention: Anti-influenza plasma plus standard care
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 98
Study: 25286891

Group type: EXPERIMENTAL
Intervention: Calf compression sleeves
Number of subjects: 11
Study: 23411647

Group type: EXPERIMENTAL
Intervention: Core stabilization exercises
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional exercises
Number of subjects: 30
Study: 19175400

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 10 mg/kg twice daily (b.i.d.)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 20 mg/kg twice daily (b.i.d.)
Number of subjects: 44
Study: 17557990

Group type: EXPERIMENTAL
Intervention: High-protein diet (22.5% protein)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard diet (15% protein)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 120
Study: 15042007

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate
Number of subjects: 385
Study: 12498134

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Anaprilin
Number of subjects: 40
Study: 9462907

Group type: EXPERIMENTAL
Intervention: Dorsiflexion night splints for 1 month
Number of subjects: 37
Study: 8535099

Group type: EXPERIMENTAL
Intervention: Enalapril (angiotensin converting enzyme inhibitor)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hypocapnic hyperventilation
Number of subjects: 9
Study: 2121911

Group type: EXPERIMENTAL
Intervention: 18 or 24 Gy radiation therapy (RT) to gonads (group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Craniospinal RT (group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cranial RT (group 3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Leydig cell function assessment (LH and testosterone)
Number of subjects: 60
Study: 105834

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31682027

Group type: EXPERIMENTAL
Intervention: Granular slow-release enteric-coated PAS 4 g twice daily
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Granular slow-release enteric-coated PAS 8 g once daily
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 29
Study: 30806619

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 487
Study: 28430910

Group type: EXPERIMENTAL
Intervention: Pitavastatin plus ezetimibe (intensive LDL-C lowering, target LDL-C < 70 mg/dL)
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Pitavastatin monotherapy (standard LDL-C lowering, target LDL-C 90-100 mg/dL)
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: Pitavastatin plus ezetimibe (in patients with higher cholesterol absorption)
Number of subjects: 1734
Study: 25872666

Group type: EXPERIMENTAL
Intervention: Excision of the pit of the sinus followed by phenol applications of the sinus tract
Number of subjects: 100

Group type: COMPARATOR
Intervention: Radical surgical excision of the sinus
Number of subjects: 100
Study: 23323901

Group type: EXPERIMENTAL
Intervention: Crisis checklists
Number of subjects: 17

Group type: COMPARATOR
Intervention: Memory alone (no checklists)
Number of subjects: 17
Study: 21113615

Group type: EXPERIMENTAL
Intervention: Racewalking at 10.9 ± 1.0 km h(‐1) (Walk)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Running at the same velocity (RunVel)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Running at 13 ± 1.8 km h(‐1) (Run[Formula: see text])
Number of subjects: 9
Study: 19111995

Group type: EXPERIMENTAL
Intervention: Virtual reality relaxation plus intravenous morphine PCA infusion
Number of subjects: 88

Group type: COMPARATOR
Intervention: Intravenous morphine PCA infusion alone
Number of subjects: 88
Study: 17485449

Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 20
Study: 15297305

Group type: EXPERIMENTAL
Intervention: Multiple intervention including group education meetings, consensus procedure on antibiotic indication and type, communication skills training, monitoring and feedback on prescribing behaviour, education for assistants and pharmacists, and educational material for patients.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multiple intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Multiple intervention and Control group
Number of subjects: 100
Study: 11890487

Group type: EXPERIMENTAL
Intervention: Haloperidol 1 to 5 mg/day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Trazodone 50 to 250 mg/day
Number of subjects: 28
Study: 9673476

Group type: EXPERIMENTAL
Intervention: Polyacrylic acid 0.2% (PAA) gel
Number of subjects: 89

Group type: COMPARATOR
Intervention: Polyvinyl alcohol 1.4% (PVA)
Number of subjects: 89
Study: 7989638

Group type: EXPERIMENTAL
Intervention: Three-phase sequential treatment strategy
Number of subjects: 119
Study: 2692290

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 0
Study: 31578418

Group type: EXPERIMENTAL
Intervention: Critical care case John
Number of subjects: 0

Group type: COMPARATOR
Intervention: Critical care case Jane
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Male responders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Female responders
Number of subjects: 0
Study: 28121041

Group type: EXPERIMENTAL
Intervention: Extended antibiotic prophylaxis (intravenous cefuroxime 750 mg plus metronidazole 500 mg, three times daily for 3 days after surgery)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard prophylaxis (single preoperative dose of cefazolin 2000 mg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Extended antibiotic prophylaxis
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard prophylaxis
Number of subjects: 150
Study: 26501562

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Balance training
Number of subjects: 40
Study: 23811059

Group type: EXPERIMENTAL
Intervention: E-mailed personalized feedback
Number of subjects: 191

Group type: COMPARATOR
Intervention: E-mailed generic feedback
Number of subjects: 191
Study: 19939481

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1669
Study: 19181821

Group type: EXPERIMENTAL
Intervention: Intensive intervention group (n = 83)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Usual care group (n = 85)
Number of subjects: 168
Study: 17537011

Group type: EXPERIMENTAL
Intervention: Turquoise light (OSRAM L18W/860 fluorescent lamps)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blue light (Philips TL20W/52 fluorescent lamps)
Number of subjects: 0
Study: 14999598

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha 2b plus ribavirin for 48 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous nondetectability of virus load in serum for 36 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous nondetectability of virus load in serum for 32 weeks
Number of subjects: 0
Study: 12494609

Group type: EXPERIMENTAL
Intervention: Fusion Avoidance (FA) On
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: AICS activated
Number of subjects: 38